NMA: Nonprescription Medicines Academy

Patient Safety Alerts

May 29th, 2013

All Acetaminophen Products on FDA Watch List
The FDA has added all acetaminophen-containing products to its quarterly list of products to monitor because of possible signals of serious risks or new safety information. FDA is continuing to evaluate the issue of severe skin reactions to determine the need for any regulatory action.

FDA Targets Dimethylamylamine Supplements
The FDA is using all available tools at its disposal to ensure that dietary supplements containing the stimulant dimethylamylamine (DMAA) are no longer distributed and available for sale to consumers. DMAA is used most commonly in supplements promising weight loss, muscle building, and performance enhancement; it can elevate blood pressure and could lead to cardiovascular problems, including heart attack, shortness of breath and tightening of the chest. DMAA may be particularly dangerous when used with caffeine. As of April 11, 2013, the FDA had received 86 reports of illnesses and death associated with supplements containing DMAA.